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ABSTRACT
Background and Objectives: Vascular perturbation induced by advanced glycation end-products (AGEs) leads to progres-
sion of atherosclerosis, plaque instability, and vascular inflammation, which results in a higher risk of neointimal proliferation. 
Here we investigated the inhibitory effect of alagebrium chloride (ALT-711), a breaker of AGE-based cross links, on neointi-
mal proliferation in a carotid artery balloon injury model in diabetic rats induced by streptozotocin (STZ). Materials and Meth-
ods: Rat aortic vascular smooth muscle cells (RASMCs) were treated with 1-100 μM of alagebrium added 24 hours before the 
addition of AGEs. This in vivo study was done using 8-week-old male rats that were injected intraperitoneally with 80 mg/kg 
STZ. Sixteen weeks later, the diabetic rats were treated with 10 mg/kg alagebrium for 4 weeks, after which carotid artery bal-
loon injury was induced. After 4 weeks, the animals were sacrificed for histological analysis. Results: Proliferation of RASMCs 
was significantly inhibited in alagebrium-treated cells. Alagebrium dose-dependently inhibited AGE-mediated formation of 
reactive oxygen species (ROS), extracellular signal-regulated kinase phosphorylation, and cyclooxygenase-2 expression. The 
cellular mechanisms of AGE-induced connective tissue and extracellular matrix expression were decreased in the alagebrium-
treated group. This in vivo study shows that expression of AGE receptors and neointima hyperplasia are significantly suppressed 
in balloon-injured rats treated with alagebrium. Conclusion: Alagebrium treatment in diabetic rats significantly inhibits neo-
intimal hyperplasia after carotid balloon injury due to its inhibition of intracellular ROS synthesis, which results in inhibition of 
RASMCs proliferation. (Korean Circ J 2010;40:520-526)
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Introduction
Although coronary artery restenosis has decreased signifi-
cantly in the era of drug-eluting stents, it remains a significant 
clinical problem, one that affects 10% of patients with stents 
and a significantly higher restenosis rate in diabetics.
1-3) There-
fore, further improvement in drug eluting stent (DES) delivery 
and optimal supportive pharmacological therapy may be requir-
ed to improve clinical outcomes in diabetic patients.
4) It is as-
sumed that excessive neointimal formation in diabetes is due 
to exaggerated inflammatory reactions at the site of injury, in-
creased migration and proliferation of vascular smooth mus-
cle cells, and excessive synthesis of extracellular matrix.
2)3)5) How-
ever, the pathogenic mechanisms leading to the increased re-
stenosis rate in diabetics are poorly understood.
A recent report showed that long-standing hyperglycemia 
leads to generation of advanced glycation end-products (AGEs), 
which are the products of nonenzymatic glycation and oxida-
tion of proteins and lipids, and their accumulation repairs 
vessel wall formation and vascular perturbations that lead to 
progression of atherosclerosis and plaque instability.
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over, AGEs are reported to have a role in neointimal forma-
tion in animal models of arterial stenosis.
12-14) In these reports, 
receptors for AGEs play a key role in neointimal formation 
after vascular injury, irrespective of diabetes status, and these 
findings suggest a novel target for minimizing neointimal hy-
perplasia.
13-18) These processes lead to progression of athero-
sclerosis, plaque instability, and the emergence of clinical events. 
AGE-mediated cross-link formation in proteins such as colla-
gen may result not only in stiffening of the arteries, but also in 
increased extracellular matrix formation and increased vas-
cular inflammation, which results in increased risk of neointi-
mal proliferation.
7)19-21) AGE accumulation and formation of 
cross links are associated with increased proinflammatory cy-
tokine levels and increased expression of AGE receptors (RAG-
Es), resulting in increased vascular inflammation.
16)21)22)
In this study, we hypothesized that alagebrium chloride (ALT-
711), an AGE cross link breaker, would inhibit neointimal 
proliferation through the above-mentioned mechanisms in 
a streptozotocin (STZ)-induced diabetic rat carotid artery bal-
loon injury model.
Materials and Methods
Animal experiments
Healthy male Sprague-Dawley rats that weighed 200-250 g 
received intraperitoneal injections of STZ (Sigma, St Louis, MO, 
USA) at a dose of 80 mg/kg. The rats, which develop diabetes, 
then received long-acting insulin (2 U/day daily) after the STZ 
injection. Sixteen weeks later, rats were randomized into two 
study groups: an alagebrium (10 mg/kg) treatment group (n= 
4) and a control group (n=4). The alagebrium chloride was 
mixed with pulverized standard chow to a final alagebrium 
concentration of 0.015% (wt/wt). Treatment of rats with drug 
mixed with chow was continued for 4 weeks. Then, carotid ar-
tery balloon injury was induced. After 4 weeks, animals were 
sacrificed for histological analysis of the injured carotid artery. 
 
Isolation and culture of rat aortic vascular smooth 
muscle cells
 Rat aortic vascular smooth muscle cells (RASMCs) were iso-
lated as previously described.
23) RASMCs were cultured in 
DMEM supplemented with 10% fetal bovine serum, 100 IU/
mL penicillin, and 100 μg/mL streptomycin in 75-cm
2 flasks 
at 37°C in a humidified atmosphere of 95% air and 5% CO2 
(Therno Scientific Inc., Asheville, NC, USA).
Cell proliferation assay
RASMCs were plated in triplicate wells of 96-well plates at 
a density of 1×10
4 cells per well. Pretreatment with alagebri-
um was done 3 hours prior to exposure to AGEs (50 μg/mL) 
for 3 hours. After treatment of cells, 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (Sig-
ma, USA) was added to each well to a final concentration of 
0.5 mg/mL and cells were incubated at 37°C for 3 hours to al-
low MTT reduction. The formazan crystals were dissolved by 
adding dimethylsulfoxide (DMSO) and absorbance was meas-
ured at 570 nm with a spectrophotometer.
 
Measurement of intracellular reactive oxygen 
species generation
To measure reactive oxygen species (ROS) generation, RA-
SMCs were labeled with 2’, 7’-dichlorodihydrofluorescein di-
acetate (H2DCFDA; of 5 mM, Invitrogen, Carlsbad, CA, USA). 
Quiescent cells were treated with alagebrium and/or AGEs 
before labeling with H2DCFDA. Labeled cells were incubated 
at 37°C in a cell culture incubator for 10 minutes. Cells were 
then analyzed by fluorescence using an excitation wavelength 
of 480 nm and emission light at 535 nm and a confocal micro-
scope (Carl Zeiss, Inc., Thornwood, NY, USA). 
Reverse transcription polymerase chain reaction 
analysis 
Expression levels of various proteins were analyzed by re-
verse transcription polymerase chain reaction (RT-PCR). To-
tal ribonucleic acid (RNA) was prepared by the Ultraspect
TM-
II RNA method (Biotecx Laboratories, Inc., Houston, TX, USA) 
and single-stranded complementary deoxyribonucleic acid 
was synthesized from isolated total RNA by Avian Myeloblas-
tosis virus (AMV) reverse transcriptase. Twenty μL of reverse 
transcription reaction mixture containing 1 g of total RNA, 
1X reverse transcription buffer (10 mM Tris-HCl, pH 9.0, 50 
mM KCl, 0.1% Triton X-100), 1 mM deoxynucleoside tripho-
sphates (dNTPs) 0.5 unit of RNase inhibitor, 0.5 g of oligo (dT)15 
and 15 units of AMV reverse transcriptase were incubated at 
42°C for 15 minutes, heated to 99°C for 5 minutes, and then 
incubated at 4°C for 5 minutes. PCRs were done for 35 cycles 
with 3’ and 5’ primers based on the sequences of various genes. 
Primers were as follows: RAGE: 5’-GGCCTTCCTCGGCG-
CAGACC-3’, 5’-TAGATGCCCTCATCCTCATGC-3’ (260 
bp); COX-2: 5’-TCCAATCGCTGTACAAGCAG- 3’,5’-T 
CCCCAAAGATAGCATCTGC-3’ (230 bp); Collagen type 
III: 5’-AGATGCTGGTGCTGAGAAG-3’, 5’-TGGAAAGA 
AGTCTGAGGAAGG-3’ (312 bp); Fibronectin: 5’-GTGAA-
GAACG-AGGAG-GATGT-G-3’, 5’-GTGATGGCGGAT-
GATGTAGC-3’ (300 bp); Connective tissue growth factor 
(CTGF): 5’-AAGAAGACTCAGCCAGACC-3’, 5’-AGAG-
GAGGAGCACCAAGG-3’ (235 bp). Glyceraldehyde phos-
phate dehydrogenase (GAPDH): 5’-ACCACAGTCCATGC-
CATCAC-3’, 5’-TCCACCACCCTGTTGCTGTA-3’ (450 
bp). The signal intensity of the amplification product was nor-
malized to its respective GAPDH signal intensity.
Immunoblot analysis 
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in a lysis buffer (Cell Signaling Technology, Inc., Danvers, MA, 
USA) containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM 
Na2 ethylenediaminetetraacetic acid, 1 mM ethyleneglycol-
tetraacetic acid, 1% Triton, 2.5 mM sodium pyrophosphate, 
1 mM β-glycerophosphate, 1 mM Na3VO4, 1 mg/mL leupep-
tin and 1 mM PMSF. Protein concentrations were determined 
using the Bradford protein assay kit (BioRad, Hercules, CA, 
USA). Proteins were separated in a 12% SDS-polyacrylamide 
gel and transferred to polyvinyliclene membrane (Millipore 
Co., Billerica, MA, USA). After blocking the membrane with 
Tris-buffered saline-Tween 20 (TBS-T, 0.1% Tween 20) conta-
ining 5% non-fat dried milk for 1 hour at room temperature, 
membranes were washed twice with TBS-T and incubated 
with primary antibodies for 1 hour at room temperature or for 
overnight at 4°C. The following primary antibodies were used: 
rabbit anti-extracellular signal-regulated kinase (ERK), mouse 
anti-phospho ERK (Santa Cruz Biotechnology, USA). The mem-
branes were washed three times with TBS-T for 10 minutes, 
and then incubated for 1 hour at room temperature with hor-
seradish peroxidase-conjugated secondary antibodies. After 
extensive washing, the bands were detected by enhanced che-
miluminescence reagent (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). The band intensities were quantified using 
a Photo-Image System (Molecular Dynamics, Sweden).
Carotid artery balloon injury model
Animals were anesthetized with intraperitoneal ketamine (80 
mg/kg). After anesthesia, the left carotid artery was exposed by 
cervical midline excision. The proximal portion of the left 
common carotid artery and the origin of the left internal carotid 
artery were temporarily ligated with surgical threads to prevent 
excessive bleeding during the balloon catheter insertion. Part 
of the external carotid artery wall was excised after which a 2-Fr 
Fogarty balloon catheter (Baxter Healthcare Corp., City, St-
ate, Deerfield, IL, USA) was inserted. After the insertion of 
the balloon catheter, the temporarily-ligated proximal left com-
mon carotid artery was untied and the catheter was advanced 
towards the direction of the ascending aorta. The balloon was 
inflated just enough to develop a mild resistance against the 
arterial wall (0.2 mL). The expanded balloon catheter was than 
pulled back to inflict uniform injury along the entire common 
carotid artery wall. This procedure was repeated 3 times for 
complete denudation of the intima, after which the catheter was 
removed and the proximal external carotid artery was ligated. 
Sham operations were performed on the right common carot-
id arteries.
Histology and immunohistochemistry 
The vessels were perfusion-fixed overnight with 10% (v/v) neu-
tral-buffered formaldehyde, transversely sectioned into serial 
thick sections, and embedded in paraffin using routine me-
thods. Sections that were 2 μm thick were mounted on gela-
tin-coated glass slides to ensure that different stains could be 
used on successive sections of tissue cut through the areas of 
balloon injury. After deparaffinization and rehydration, the 
sections were analyzed with mouse anti-RAGE (Santa Cruz 
Biotechnology). Expression of RAGE was visualized by add-
ing 3,3-diaminobenzidine (Vector Laboratories, Burlingame, 
CA, USA) for 5 minutes. All images were made using virtual 
microscopy (Universal Imaging Corp., USA). Neointimal ar-
eas were visualized by Hematoxylin and eosin staining and qu-
antified using Image J Program (NIH, USA).
Statistical analysis
Data are presented as mean±SEM of more than three sepa-
rate experiments each done in triplicate. Where results of blots 
and RT-PCR are shown, a representative experiment is depict-
ed. Comparisons between multiple groups were done with 
one-way analysis of variance and Bonferroni’s test. Statistical 
significance was defined as *p<0.05 and **p<0.01.
Results
Anti-proliferative effect of alagebrium in advanced 
glycation end-product-stimulated rat aortic vascular 
smooth muscle cells
AGE-treatme nt of cells (50 μg/mL) caused a marked increa-
se (about 30%) in the number of cells. Alagebrium treatment 
along with AGE inhibited the proliferation of RASMCs. Pre-
treatments using 1 to 100 μM alagebrium significantly inhibit-
ed RASMC proliferation in a dose-dependent manner (Fig. 1). 
This demonstrated the antiproliferative effect of alagebrium 
on AGE-stimulated proliferation of RASMCs.
Effect of alagebrium on the formation of intracellular
reactive oxygen species in rat aortic vascular
smooth muscle cells
Following a 3 hours incubation of RASMCs with AGEs, ROS 
Fig. 1. Anti-proliferative effect of alagebrium in AGE-stimulated RA-
SMCs. AGE promotes proliferation of RASMCs, but alagebrium 
dose-dependently inhibits proliferation of RASMCs (*p<0.05 vs. con-
trol; †p<0.01 vs. AGE-treated group). AGE: advanced glycation end-
product, RASMCs: rat aortic vascular smooth muscle cells. 
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production was dose dependently increased, indicating that 
AGEs could be a growth stimulator of RASMCs. There was a 
significant increase in ROS formation in cells treated with 50 
to 100 μg/mL AGEs (Fig. 2A). In order to determine whether 
alagebrium modifies the effect of AGEs on ROS production 
by RASMCs, cells were pretreated with various concentrations 
of alagebrium for 30 minutes prior to exposure to AGEs (50 
μg/mL). Alagebrium-treatment of RASMCs reduced the for-
mation of ROS in a dose-dependent manner (Fig. 2B).
 
Changes in mitogen-activated protein kinase and
reactive oxygen species-related signaling 
in alagebrium-treated rat aortic vascular smooth 
muscle cells
Cells exposed to 1 and 10 μM of alagebrium were treated 
with 50 μg/mL of AGEs. Mitogen-activated protein kinase (MA-
PK) signaling was inhibited-by 35% and 42%, respectively-
by pretreatment with 1 and 10 μM of alagebrium (Fig. 3A). To 
determine the relationship between ROS production and ERK 
activation in RASMCs, COX-2 expression was determined by 
RT-PCR. The results showed that COX-2 mesenger ribonu-
cleic acid (mRNA) expression increased by 2.15-fold after in-
cubation with 50 μg/mL of AGEs. However, pretreatment with 
alagebrium resulted in significant inhibition (up to 50%) of 
the expression of COX-2 in AGE-stimulated cells in the 10 μM 
alagebrium treatment group (Fig. 3B).
Inhibitory effects of alagebrium on expression 
of connective tissue and extracellular matrix 
in advanced glycation end-product-stimulated 
rat aortic vascular smooth muscle cells
As illustrated in Fig. 4, AGE (50 μg/mL) treatment for 24 
hours markedly increased mRNA expression for collagen 
type III, fibronectin, and CTGF. However, alagebrium-treated 
cells showed dose-dependent abolition of collagen type III, 
fibronectin and CTGF mRNA levels at each dose of alagebri-
Fig. 2. Effect of AGE and alagebrium on the formation of intracellular ROS in RASMCs. AGEs dose-dependently stimulated growth of RASMCs. 
Alagebrium reduced the formation of reactive oxygen species (*p<0.05 vs. CTL; vs. AGE-treated group). AGE: advanced glycation end-prod-
uct, ROS: reactive oxygen species, RASMCs: rat aortic vascular smooth muscle cells, DCF: 2'-7'-dichlorofluorescin, CTL: control.
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um. The mRNA expression level of collagen type III decreased 
significantly in the alagebrium-treated group compared to 
AGE alone (Fig. 4A). 
Also, the expression of fibronectin was significantly di-
minished in the alagebrium treatment group by about 27% 
and 47% each, compared to the AGE treatment group (Fig. 
4B). Finally, CTGF expression was down-regulated by approx-
imately 12.5% and 46%, respectively, after pretreatment with 
1 μM and 10 μM of alagebrium (Fig. 4C).
Effect of alagebrium on the expression of advanced
glycation end-product receptor in rat aortic vascular
smooth muscle cells
The carotid balloon injury rat model was associated with a 
markedly increased expression of RAGE, which was signifi-
cantly attenuated in alagebrium-treated rats (Fig. 5A). Also, 
analysis of RAGE expression in neointimal tissue, as deter-
mined by RT-PCR, showed that alagebrium (1 and 10 μM) dose-
dependently inhibited the expression of RAGE (by approxi-
mately 17% and 84%, respectively) (Fig. 5B).
Alteration of extra-cellular matrix and neointima 
formation by alagebrium after balloon-injury 
of diabetic rats
Alagebrium was administered daily for 4 weeks prior to bal-
loon injury using the carotid artery balloon injury diabetic rat 
model. Withdrawal of the inflated balloon resulted in vascu-
lar injury leading to neointima formation. Four weeks after in-
jury, the inner vessel surface was covered with one or several 
layers of ovoid, irregularly-shaped cells forming the neointima. 
Fig. 6 shows that neointimal formation in the alagebrium 
treatment group after balloon injury was significantly lower 
than in controls, in STZ-treated rat given alagebrium after bal-
loon injury there was no further neointimal growth. At this time, 
the neointimal area in STZ-treated rat given alagebrium was 
reduced significantly by about 69% compared with control 
(Fig. 6B).
 
Discussion
Our study demonstrates that alagebrium chloride inhibits 
Fig. 4. Effects of alagebrium on expression of CTGF and ECM in AGE-stimulated RASMCs. AGE (50 μg/mL) treatment for 24 hours markedly in-
creased messenger ribonucleic acid expression of collagen type III (A), fibronectin (B) and CTGF (C) in RASMCs. Alagebrium (1 and 10 μM) 
dose-dependently abolished this effect (*p<0.05 vs. AGE-treated group, **p<0.01 vs. AGE-treated group). CTGF: connective tissue growth fac-
tor, ECM: extra-cellular matrix, AGE: advanced glycation end-products, RASMCs: rat aortic vascular smooth muscle cells. 
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neointimal proliferation in a STZ-induced diabetic rat carot-
id artery balloon injury model. To our knowledge, this is the 
first report to show that alagebrium can directly inhibit the 
pro-atherosclerotic effect of AGE on RASMCs. These effects 
of alagebrium were mediated by inhibition of ERK signaling 
and down-regulation of COX-2 mRNA expression via re-
duction of intracellular ROS levels that had been induced by 
AGE. Furthermore, we found that the anti-proliferative effect 
of alagebrium resulted from inhibition of RAGE expression.
Macrovascular complications develop in >50% of the dia-
betic population and account for 50-60% of the mortality in 
this high-risk group.
1) Dyslipidemia, hypertension, and hyper-
glycemia all play roles in the development of diabetes-associ-
ated atherosclerosis, although the specific contributions from 
each of these independent risk factors remain controversial. 
Previous studies that used exogenous administration of AGEs 
to mimic diabetic serum concentrations indicated that AGEs 
can induce atherosclerosis.
9-11) Furthermore, AGEs interact 
with endothelial cells to induce the expression of atherogen-
ic adhesion molecules implicated in atherogenesis. 
Studies in experimental obese Zucker rats, a model of insu-
lin resistance induced by the AGE formation inhibitor pyri-
doxamine, have shown marked attenuation of the character-
istic hyperlipidemia, reduced AGEs, and hypertension, in-
dicating interactions between AGEs and lipids.
22) One of the 
seminal in vivo studies performed in experimental diabetes-
Fig. 5. Effect of alagebrium on the expression of RAGE in balloon-injured rats. A: RAGE expression was significantly decreased by alagebrium 
treatment in vivo, which was confirmed by immunohistochemistry. All sections were observed by virtual microscopy (magnification: left, ×200; 
right, ×400). B: AGE group increased expression of messenger ribonucleic acid for RAGE. This effect was significantly attenuated by alagebrium 
(*p<0.05 vs. AGE-treated group). RAGE: advanced glycation end-product receptor. 
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associated atherosclerosis demonstrated attenuation of plaque 
formation by the soluble receptor for AGEs (sRAGE).
21)
More recently, therapeutic approaches have involved the 
use of a thiazolium derivative, alagebrium, a compound that 
suggested to be capable of breaking AGE cross-links, and th-
ereby removing preformed AGEs.
6-8) Alagebrium has proved 
successful as an intervention for established diabetic micro-
vascular complications, and has also been reported to impro-
ve vascular compliance in aging humans. Other studies of di-
abetics have shown that alagebrium attenuates both cardiac 
and renal accumulation of AGEs in association with benefits 
for patients with renal and cardiac injury.
11)15-17) AGE forma-
tion may contribute to the progression of atherosclerosis, par-
ticularly in those with diabetes. AGEs can pass through cell 
membranes via RAGE and stimulate MAPKs to cause prolif-
eration. The present study shows the inhibitory effects of al-
agebrium on RASMCs proliferation (Fig. 1) and ROS produc-
tion (Fig. 2). The mechanism of increased cell survival and 
proliferation may involve phosphorylation of ERKs (42 and 
44 kDa). Our results represent the inhibitory effects of alage-
brium on ERK activation and COX-2 inhibition (Fig. 3). The 
activation of ERKs plays an important role in gene regula-
tion, and ERK is one of several dual-specificity kinases in the 
MAPK family. Thus, the inhibition of ERK may a main mecha-
nism in the anti proliferative effect of alagebrium. Because 
COX-2 expression is associated with ROS production and 
ERK activation,  the inhibition of COX-2 expression with the 
subsequent attenuation of oxidative stress and ERK activation 
may also be an important mechanism to explain the efficacy 
of alagebrium on attenuating neointimal hyperplasia. Alage-
brium also inhibited the increase in formation of connective 
tissue and extracellular matrix (Fig. 4). Immunohistochemi-
cal staining of newly formed neointima showed a significant 
reduction in RAGE expression (Fig. 5) with significant sup-
pression of neointima formation in alagebrium-treated bal-
loon injured diabetic rats (Fig. 6). The breakdown of AGEs in 
the vascular wall may reduce the expression of RAGE, which 
is known to be positively regulated, which may result in re-
duced activation of ERK and a decrease in oxidative stress.
In conclusion, alagebrium inhibits neointimal hyperplasia 
after carotid balloon injury because it blocks intracellular 
ROS synthesis and ERK activation, resulting in inhibition of 
RASMCs proliferation. The inhibitory effect of alagebrium 
on neointimal formation may also be mediated by reduction 
of ECM production. 
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